Ongoing Research

 
News Articles for Ongoing Research top ^
PNM Resources’ (NYSE: PNM) management today announced the company’s 2015 ongoing earnings guidance range of $1.50 to $1.62 per diluted share.
Sign-up for PNM Resources Announces 2015 Ongoing Earnings Guidance Range investment picks
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers SAN FRANCISCO, Dec.
Sign-up for Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies investment picks
PNM Resources (NYSE: PNM) will announce the company's 2015 ongoing earnings guidance range prior to the market opening on Monday, Dec.
Sign-up for PNM Resources to Announce 2015 Ongoing Earnings Guidance Dec. 15 investment picks
2014/12/12
Company does not expect to make the cash interest payment due December 31 on convertible debentures VANCOUVER , Dec.
Sign-up for Ivanhoe Energy provides update on the status of ongoing strategic and financial initiatives to obtain additional financing investment picks
AuRico Gold Receives C$20 Million Upfront Payment and Ongoing Royalty with Crocodile Gold Canada NewsWire TORONTO , Jan.
Sign-up for AuRico Gold Receives C$20 Million Upfront Payment and Ongoing Royalty with Crocodile Gold investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data from clinical trials of Soliris ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), as well as an update from the Global aHUS Registry, at Kidney Week 2014, the annual meeting of the American Society of Nephrology, in Philadelphia.
Sign-up for Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment investment picks
Hydrocarb Energy Corporation (OTCQB: HECC) confirmed ongoing discussions with several international energy firms expressing interest in the company’s Owambo Basin Concession in Namibia.
Sign-up for Hydrocarb Energy Corporation Announces Ongoing Joint Venture Discussions investment picks
Monsanto Company (NYSE: MON) delivered earnings per share for the first quarter of fiscal year 2015 ahead of expectations it outlined at the beginning of the fiscal year, with the company confirming full-year ongoing earnings per share growth and free cash flow guidance.
Sign-up for Monsanto First-Quarter Milestones Reinforce Foundation for Growth in FY15 and Confidence in Five-Year Plan to More Than Double Ongoing EPS investment picks
Major infrastructure investments , including pipelines, offices and housing, are keeping major oil companies interested in Texas’ Permian Basin despite softening oil prices in recent weeks, and Taylor Consulting Inc. (OTCBB:TAYO) CEO Scott Wheeler says the company isn’t slowing down its real estate acquisition plans in the Cline Shale area in the western part of the state.
Sign-up for ‘What’s Good for the Oil Business is Good for TAYO,’ CEO Says of Ongoing Infrastructure Investments in West Texas investment picks
Company Moves Into Larger Space in New Signature Building in 22@Barcelona Technology Park that, Over Time, will Enable Employee Capacity to Grow from 450 to 700 People ROSELAND, N.J. , and BARCELONA, Spain , Nov.
Sign-up for ADP® Announces Expansion in Spain to Meet Ongoing Client Needs for Human Capital Management Technology and Expertise Around the World investment picks
Clovis Oncology (NASDAQ:CLVS) today announced initial Phase 2 results from the ARIEL2 (Assessment of Rucaparib In Ovarian Cancer Trial) study.
Sign-up for Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients investment picks
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
100% of evaluable CLL/SLL patients (9/9) had nodal reductions, with 6 of 9 patients achieving a PR with the remaining 3 patients on study with nodal reductions ranging from 15% to 45% and a peripheral response (normalization or >50% decrease in ALC) pending additional assessments 83% (5/6) of patients with Non-Hodgkin's Lymphoma; 3/3 DLBCL and 2/3 Follicular Lymphoma (FL) responded to the combination at the highest dose tested, including 2 CR's in patients with DLBCL confirmed by independent review Collectively, 87 patients have been treated with TGR-1202, alone or in combination with TG-1101, without the observance of drug-related hepatic toxicity Dose escalation continues with TGR-1202 at 800mg micronized The combination of TG-1101, TGR-1202, and ibrutinib ("Triple Therapy") was safely administered to 5 patients with heavily pre-treated NHL, CLL, and Richter's transformation with no dose limiting toxicities observed, and no Grade 3 or 4 events observed to
Sign-up for Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety investment picks
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin ® in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment.
Sign-up for NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic Nephropathy investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Ongoing Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Ongoing Earnings Guidance  |  Next: Ongoing Research Collaboration